Literature DB >> 2056624

Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma.

D L Hahn1, R W Dodge, R Golubjatnikov.   

Abstract

UNLABELLED: OBJECTIVE--To study the clinical characteristics of respiratory tract illness caused by Chlamydia pneumoniae.
DESIGN: -Prospective clinical, bacteriologic, and serologic study. Secondarily, a matched comparison of patients with and without evidence of C pneumoniae infection (serologic titers greater than or equal to 1:64 and less than 1:16, respectively).
SETTING: --Four primary care (family practice) clinics in Madison, Wis, and nearby towns. PATIENTS: --The study included 365 white males and females (mean age, 34.2 years). MAIN OUTCOME MEASURES: --Association of acute C pneumoniae infection with signs and symptoms of respiratory illness and the relationship of C pneumoniae antibody titer with wheezing at the time of enrollment in the study, and with the diagnosis of asthmatic bronchitis.
RESULTS: --Nine (47%) of 19 patients with acute C pneumoniae infection had bronchospasm during respiratory illness, and there was a strong quantitative association of C pneumoniae titer with wheezing at the time of enrollment in the study (P = .01). In the matched study, C pneumoniae antibody was significantly associated with asthmatic bronchitis after, but not before, respiratory illness (odds ratio, 7.2; 95% confidence interval, 2.2 to 23.4). Four infected patients had newly diagnosed asthma after illness, and four others had exacerbation of previously diagnosed asthma. There was no serologic evidence of coexisting Mycoplasma pneumoniae, Chlamydia trachomatis, or respiratory viral infection in 96% of patients with asthmatic bronchitis and asthma.
CONCLUSIONS: --Some C pneumoniae antibody titers, although not diagnostic of chlamydial infection by present criteria, probably represent acute reinfection or ongoing chronic infection. Repeated or prolonged exposure to C pneumoniae may have a causal association with wheezing, asthmatic bronchitis, and asthma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2056624

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  129 in total

Review 1.  Chlamydia pneumoniae and atherosclerosis: critical assessment of diagnostic methods and relevance to treatment studies.

Authors:  Jens Boman; Margaret R Hammerschlag
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

2.  Analysis of Chlamydia pneumoniae growth in cells by reverse transcription-PCR targeted to bacterial gene transcripts.

Authors:  Shusaku Haranaga; Hideaki Ikejima; Hiroyuki Yamaguchi; Herman Friedman; Yoshimasa Yamamoto
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

3.  Temporal expression of type III secretion genes of Chlamydia pneumoniae.

Authors:  Anatoly Slepenkin; Vladimir Motin; Luis M de la Maza; Ellena M Peterson
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

4.  A trial of clarithromycin for the treatment of suboptimally controlled asthma.

Authors:  E Rand Sutherland; Tonya S King; Nikolina Icitovic; Bill T Ameredes; Eugene Bleecker; Homer A Boushey; William J Calhoun; Mario Castro; Reuben M Cherniack; Vernon M Chinchilli; Timothy J Craig; Loren Denlinger; Emily A DiMango; John V Fahy; Elliot Israel; Nizar Jarjour; Monica Kraft; Stephen C Lazarus; Robert F Lemanske; Stephen P Peters; Joe Ramsdell; Christine A Sorkness; Stanley J Szefler; Michael J Walter; Stephen I Wasserman; Michael E Wechsler; Hong Wei Chu; Richard J Martin
Journal:  J Allergy Clin Immunol       Date:  2010-10       Impact factor: 10.793

Review 5.  Chlamydial persistence: beyond the biphasic paradigm.

Authors:  Richard J Hogan; Sarah A Mathews; Sanghamitra Mukhopadhyay; James T Summersgill; Peter Timms
Journal:  Infect Immun       Date:  2004-04       Impact factor: 3.441

6.  Laboratory diagnosis of Chlamydia pneumoniae infections.

Authors:  R W Peeling
Journal:  Can J Infect Dis       Date:  1995-07

7.  Community epidemiology of Chlamydia and Mycoplasma pneumoniae in LRTI in France over 29 months.

Authors:  Jacques Gaillat; Antoine Flahault; Bertille deBarbeyrac; Jeanne Orfila; Henri Portier; Jean-Pierre Ducroix; Christiane Bébéar; Charles Mayaud
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

8.  Depletion of resident Chlamydia pneumoniae through leukoreduction by filtration of blood for transfusion.

Authors:  Hideaki Ikejima; Herman Friedman; German F Leparc; Yoshimasa Yamamoto
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

9.  Production of Chlamydia pneumoniae proteins in Bacillus subtilis and their use in characterizing immune responses in the experimental infection model.

Authors:  Ulla Airaksinen; Tuula Penttilä; Eva Wahlström; Jenni M Vuola; Mirja Puolakkainen; Matti Sarvas
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

10.  Telithromycin treatment of chronic Chlamydia pneumoniae infection in C57BL/6J mice.

Authors:  Liisa Törmäkangas; Hannu Alakärppä; Denise Bem David; Maija Leinonen; Pekka Saikku
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.